Loading
A phase 3 trial of [177Lu]Lu-DOTA-TATE in pancreatic ductal adenocarcinoma, run by Novartis Pharmaceuticals, now recruiting.
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET is a phase 3 interventional study registered as NCT06784752 by Novartis Pharmaceuticals, with 240 participants planned, started 2025-05-30 and due to reach its primary completion in 2028-12-08. Interventions recorded: [177Lu]Lu-DOTA-TATE and Octreotide LAR.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/